Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Serke

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2012
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT studyM Kreuter, J Vansteenkiste, J R Fischer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pneumologie (Stuttgart, Germany)|March 11, 2010
[Prevention, diagnosis, therapy, and follow-up of lung cancer]G Goeckenjan, H Sitter, M Thomas, et al.
Pneumologie (Stuttgart, Germany)|August 11, 2011
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]G Goeckenjan, H Sitter, M Thomas, et al.
Pneumologie (Stuttgart, Germany)|December 16, 2010
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer SocietyG Goeckenjan, H Sitter, M Thomas, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2012
Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT studyM Kreuter, J Vansteenkiste, J R Fischer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancerA Kron, C Alidousty, M Scheffler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 8, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancerS Novello, V Torri, C Grohe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 28, 2022
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]S Novello, V Torri, C Grohe, et al.
Pneumologie (Stuttgart, Germany)|March 11, 2010
[Prevention, diagnosis, therapy, and follow-up of lung cancer]G Goeckenjan, H Sitter, M Thomas, et al.
Pneumologie (Stuttgart, Germany)|August 11, 2011
[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version]G Goeckenjan, H Sitter, M Thomas, et al.
Pneumologie (Stuttgart, Germany)|December 16, 2010
Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer SocietyG Goeckenjan, H Sitter, M Thomas, et al.
Pageof 4